ESG Clinical Study Results
ESG Weight Loss Advantage
In a clinical study, 91 patients underwent ESG from August 2013 through March 2016. All patients were clinically obese with a body mass index (BMI) greater than 30 kg/m² and had failed non-invasive weight loss measures, or had a BMI greater than 40 kg/m² and were either not considered as surgical candidates or had refused surgery.
Six months after the procedure, patients in the study had lost 14.4% of their total body weight, 17.6% weight loss at 12 months, and 20.9% weight loss at 24 months. In addition to sustained total body weight loss up to 24 months post procedure, ESG reduced key indicators of hypertension and diabetes and hypertriglyceridemia.
What’s more, patients not only lose weight, but also experience significant improvements in markers of diabetes, high blood pressure, blood cholesterol levels, and sleep apnea.
Clinical Studies Referenced
- Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population.
Bariatric surgery and diabetes remission: Who would have thought it?
Laparoscopic sleeve gastrectomy–influence of sleeve size and resected gastric volume.
- Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus.
Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients
San Diego Institute for Weight Loss
Average rating: 0 reviews